AC Immune SA ACIU
Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026
AC Immune SA (ACIU) is a healthcare company listed in the US with a market value of about $217M. In fiscal year 2025 it had revenue of $5M and net income of -$89M, a net margin of -1971.6%.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -24% a year, a 5-year average ROIC of -56%.
About AC Immune SA
AC Immune SA is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2016. Revenue went from $39M in 2015 to $5M in 2025, a decline of about 19.5% a year. It was profitable in 1 of the last 10 years in our data.
Score: 0.2 / 5
Checks passed
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $30M | $18M | $4M | $0 | $18M | $114M | $7M | $21M | $23M |
| Net income | -$89M | -$56M | -$65M | -$77M | -$80M | -$70M | $47M | -$52M | -$27M | -$7M |
| Free cash flow | -$89M | $72M | -$73M | -$81M | -$75M | -$70M | $55M | -$47M | -$24M | -$6M |
| EPS (diluted) | $-0.87 | $-0.55 | $-0.64 | $-0.75 | $-0.79 | $-0.69 | $0.46 | $-0.51 | $-0.27 | $-0.07 |
| Net margin | -1971.7% | -186.4% | -366.4% | -1798.0% | — | -401.3% | 41.1% | -737.1% | -130.4% | -30.6% |
| ROIC | -154.4% | -36.9% | -26.4% | -33.1% | -26.9% | -28.4% | 16.4% | -27.9% | -19.3% | -7.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does AC Immune SA pay a dividend?
Not currently.
Is AC Immune SA a good stock to buy?
We do not give buy or sell advice. AC Immune SA scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.